Standout Papers

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients wi... 2020 2026 2022 2024174
  1. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (2020)
    Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research

Immediate Impact

57 standout
Sub-graph 1 of 23

Citing Papers

Advances in diagnosis and treatment of bladder cancer
2024 Standout
Targeting ROS in cancer: rationale and strategies
2024 Standout
2 intermediate papers

Works of Aiping Zhou being referenced

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
2020 Standout
Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
2019

Author Peers

Author Last Decade Papers Cites
Aiping Zhou 280 442 326 78 932
Munita Bal 295 451 495 122 1.1k
Byoung Kwan Son 211 268 259 94 977
Michael Doukas 287 398 361 64 1.1k
Catherine Devine 338 218 250 53 999
Federica Gaiani 216 271 502 59 1.1k
William W. Shingleton 248 353 333 59 1.0k
Antonio Russo 236 199 257 63 966
E. Uchida 136 447 245 56 1.1k
Jianwei Zhang 180 258 228 79 869
Thiruvengadam Muniraj 281 430 563 76 1.1k

All Works

Loading papers...

Rankless by CCL
2026